Scholarlink

<p>Fifteen to forty% of patients experience recurrent weight gain (RWG) after metabolic bariatric surgery (MBS). Glucagon-like peptide receptor agonists (GLP-1 RAs) are effective treatments for obesity in nonsurgical patients. To assess the effects of semaglutide and tirzepatide after MBS, we conducted a meta-analysis of data from inception to August 2025. Eight retrospective studies and 964 patients were included. The percentage total weight loss (%TWL) was − 10.97% [95% CI, − 13.41 to − 8.53; <i>p</i> &lt; 0.05] for semaglutide and − 13.63% [95% CI, − 22.59 to − 4.67; <i>p</i> &lt; 0.05] for tirzepatide. The evidence suggests that semaglutide and tirzepatide result in weight reduction in patients with RWG after MBS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis

  • 期刊论文

  • 发表日期：

    2025年11月28日

查看全文
  • Angel Alois Osorio Manyari,
  • Azucena Lirio Armas Alvarez,
  • Joel Davis Osorio Manyari,
  • Francisco Onieva Gonzalez,
  • Sjaak Pouwels

摘要

Fifteen to forty% of patients experience recurrent weight gain (RWG) after metabolic bariatric surgery (MBS). Glucagon-like peptide receptor agonists (GLP-1 RAs) are effective treatments for obesity in nonsurgical patients. To assess the effects of semaglutide and tirzepatide after MBS, we conducted a meta-analysis of data from inception to August 2025. Eight retrospective studies and 964 patients were included. The percentage total weight loss (%TWL) was − 10.97% [95% CI, − 13.41 to − 8.53; p < 0.05] for semaglutide and − 13.63% [95% CI, − 22.59 to − 4.67; p < 0.05] for tirzepatide. The evidence suggests that semaglutide and tirzepatide result in weight reduction in patients with RWG after MBS.